The efficacy of leflunomide monotherapy in rheumatoid arthritis: Towards the goals of disease modifying antirheumatic drug therapy

Journal of Rheumatology

Volumn 31, Issue 7 SUPPL. 1, 2004, Pages 13-20

  Smolen, Joseph S ^a,h   Emery, Paul ^b   Kalden, Joachim R ^c   Van Riel, Piet L C M ^d   Dougados, Maxime ^e   Strand, C Vibeke ^f   Breedveld, Ferdinand C ^g  

^a GENERAL HOSPITAL LINZ   (Austria)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Hospital Cochin ^*  (France)

^f STANFORD UNIVERSITY   (United States)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Leflunomide; Monotherapy; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; UNCLASSIFIED DRUG; ISOXAZOLE DERIVATIVE;

ALOPECIA; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT RADIOGRAPHY; LEUKOPENIA; LIVER TOXICITY; MEDICAL DECISION MAKING; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; STEADY STATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MAXIMUM TOLERATED DOSE; ORAL DRUG ADMINISTRATION; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MAXIMUM TOLERATED DOSE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2542538995     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Cohen S, Cannon G, Schiff M, Weaver A, Fox R, Olsen N. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the Treatment of Rheumatoid Arthritis Investigator Group. Arthritis Rheum 2001;44:1984-92.
2. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
3. Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis - longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001;28:1983-91.
4. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology Oxford 2000;39:655-65.
5. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
6. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
7. Schiff MH, Strand V, Oed C, Loew-Friedrich I. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today Barc 2000;36:383-94.
8. Schiff M. Leflunomide versus methotrexate: a comparison of the European and American experience. Scand J Rheumatol Suppl 1999;112:31-5.
9. Kalden JR, Schattenkirchner M, Sorensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003;48:1513-20.
10. Scott D, Schattenkirchner M, Smolen JS, et al. Efficacy of leflunomide versus placebo, versus SSA in RA. Effect of disease duration [abstract]. Arthritis Rheum 1998;41 Suppl:S155.
11. Moreland L, Fleischmann R, Strand V, from the leflunomide RA Investigators Group. Efficacy of leflunomide vs placebo vs methotrexate in early and late rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl:S155.
12. Dougados M, Emery P, Lemmel E, et al. Maintenance rate of leflunomide in patients with rheumatoid arthritis: RELIEF 1-year data [abstract]. Arthritis Rheum 2001;44 Suppl:S173.
13. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
14. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74-8.
15. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology Oxford 2000;39:122-32.
16. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:495-505.
17. van der Heijde D, Kalden JR, Smolen JS, Strand V. Long term evaluation of radiographic disease progression in patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004;63 (in press).
18. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL. Patient reported outcomes better discriminate active treatment from placebo in RA clinical trials. Rheumatology Oxford: 2004; (in press).
19. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
20. Guzman J, Maetzel A, Peloso P, Yeung M, Bombardier C. Disability scores in DMARD trials. What is a clinically important change? [abstract]. Arthritis Rheum 1996;39 Suppl:S208.
21. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
22. Kosinski M, Martin R, Henkenius S, Wanke L, Buatti M. Determining clinically meaningful improvement in SF-36 scale scores for treatment studies in rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl:S140.
23. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337-42.
24. Samsa G, Edelmann D, Rothman M, Williams G, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Index Mark 11. Pharmacoeconomics 1999;15:141-55.
25. Thumboo J, Fong K, Ng T, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999;26:97-102.
26. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
27. Weber W, Harnisch L. Use of a population approach to the development of leflunomide: A new disease-modifying drug in the treatment of rheumatoid arthritis. In: Aarons L, Balant LP, Danhof M, et al, editors. European cooperation in the field of scientific and technical research. Brussels: European Commission Directorate-General Science, Research and Development, 1997:239-44.
28. Chokkalingham S, Shepherd R, Cunningham F, Eisen S. Leflunomide use in the first 33 months after FDA approval: Experience in a national cohort of 3325 patients [abstract]. Arthritis Rheum 2002;46 Suppl:S538.
29. Dougados M, Antoine C, Brin S, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003;30:2572-9.
30. van Riel PLCM, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol 2004;31 Suppl 71:xxxx.
31. Smolen J, Breedveld F, Schiff M, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology Oxford 2003;42:244-57.